Morgan Stanley Assumes ShockWave Medical at Equal-Weight, Announces Price Target of $291
Portfolio Pulse from richadhand@benzinga.com
Morgan Stanley analyst Patrick Wood assumes coverage of ShockWave Medical (NASDAQ:SWAV) with an Equal-Weight rating and a price target of $291.
May 30, 2023 | 11:32 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Morgan Stanley analyst Patrick Wood initiates coverage on ShockWave Medical with an Equal-Weight rating and a price target of $291.
Morgan Stanley's initiation of coverage on ShockWave Medical with an Equal-Weight rating suggests a neutral outlook for the stock in the short term. The price target of $291 indicates the analyst's expectation for the stock's future performance. This news is directly related to SWAV and is important for investors, but the neutral rating suggests no immediate impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100